A number of disease-severity and quality-of-life (QoL) instruments have emerged in atopic dermatitis (AD) in the last decade.
To identify trends in outcomes instruments used in AD clinical trials and to provide a useful summary of the dimensions and validation studies for the most commonly used measures.
All randomized control trials (RCTs) from 1985 to 2010 in the treatment of AD were examined.
Among the 791 RCTs reviewed, we identified 20 disease-severity and 14 QoL instruments. Of these outcomes instruments, few have been validated. SCORAD, EASI, IGA and SASSAD were the most commonly used disease-severity instruments and CDLQI, DFI, DLQI and IDQOL were the most frequently used QoL measures.
The small number of RCTs using QoL scales makes identifying trends for QoL instruments difficult.
Overall, there is an increase in the use of disease-severity and QoL instruments in AD clinical trials.
Publisher: Public Library of Science
Date Published: 13-April-2011
Author(s): Rehal B., Armstrong A.